Nyfors S, Syrjänen R, Könönen E
Department of Microbiology, Anaerobe Reference Laboratory, National Public Health Institute (KTL), Mannerheimintie 166, FIN-00300 Helsinki, Finland.
Int J Antimicrob Agents. 2004 Nov;24(5):463-7. doi: 10.1016/j.ijantimicag.2004.06.014.
Beta-lactamase production by oral bacteria is common in infancy and is associated with use of antimicrobial agents in infants. The present longitudinal study aimed to examine the frequency of salivary beta-lactamase activity (SbetaA), to compare SbetaA with the presence of beta-lactamase-producing (beta+) aerobic and anaerobic species in saliva, and to estimate the impact of antimicrobial exposure on the emergence of SbetaA in healthy infants during their first year of life. At 6 months, SbetaA was detected in 46% infants; 89% SbetaA-positive infants and 55% SbetaA-negative infants harboured beta+ species at this time (OR 7.08; CI 1.31-38.34). At 12 months, SbetaA was detected in 54% infants. Exposure to antimicrobials during the first year of life increased the risk (OR 2.60; CI 0.72-9.36) of having SbetaA.
口腔细菌产生β-内酰胺酶在婴儿期很常见，且与婴儿使用抗菌药物有关。本纵向研究旨在检测唾液β-内酰胺酶活性（SbetaA）的频率，比较SbetaA与唾液中产生β-内酰胺酶的（β+）需氧菌和厌氧菌的存在情况，并评估抗菌药物暴露对健康婴儿出生后第一年SbetaA出现的影响。6个月时，46%的婴儿检测到SbetaA；此时，89%的SbetaA阳性婴儿和55%的SbetaA阴性婴儿携带β+菌（比值比7.08；可信区间1.31 - 38.34）。12个月时，54%的婴儿检测到SbetaA。出生后第一年接触抗菌药物会增加出现SbetaA的风险（比值比2.60；可信区间0.72 - 9.36）。
